APONTIS PHARMA continues to gear organization towards growth and internationalization – Renowned industry expert leads supply chain management

APONTIS PHARMA continues to gear organization towards growth and internationalization – Renowned industry expert leads supply chain management
 

• Mila Brückel appointed as Head of Supply Chain

• Extensive expertise in managing global supply chain programs from positions at Merck Healthcare

Monheim / Rhein, 4 June 2024. APONTIS PHARMA AG (Ticker APPH / ISIN DE000A3CMGM5), a leading pharmaceutical company specializing in Single Pill combinations in the German market, continues to gear its organization towards the planned company growth and the upcoming internationalization. To this end, the Company has appointed Mila Brückel, a renowned industry expert and supply chain specialist, as Head of Supply Chain.

Since 3 June 2024, Mila Brückel has been responsible for all aspects of supply chain management at APONTIS PHARMA, including demand forecasting, procurement, inventory management, new product launches, and distribution to customers. In her new role, she reports directly to CEO Bruno Wohlschlegel.

Mila Brückel has more than 25 years of experience in supply chain management – including 15 years in the pharmaceutical sector – and joins APONTIS PHARMA from Merck Healthcare, the healthcare segment of Merck KGaA, a leading global pharmaceutical and chemical company. There she was Head of Supply Chain for the German pharmaceutical business and before that responsible for the global supply chain of General Medicine Classics and diabetes products, among other things. Prior to Merck Healthcare, Mila Brückel was responsible for the supply chain at Airwell Germany.

Bruno Wohlschlegel, CEO of APONTIS PHARMA: “Mila Brückel is a renowned expert in supply chain management in the pharmaceutical industry. With her appointment, we are taking this area of our company to a new level by adding top-class talent. Mila's experience in managing global supply chain programs will help us to optimally align our increasingly complex product portfolio with demand and prepare us for the challenges of our upcoming internationalization. I look forward to working with her.”

Additional information:

Information on upcoming events can be found at https://apontis-pharma.de/en/financial-calendar and the latest analyst assessments at https://apontis-pharma.de/en/share-price.

About APONTIS PHARMA:

APONTIS PHARMA AG is a leading pharmaceutical company specializing in Single Pill combinations in Germany. Single Pills combine two to three generic active ingredients in a single dosage form administered once a day. Single Pill therapies have been scientifically proven to significantly increase adherence and thus improve the treatment prognosis and quality of life of patients while reducing complications, mortality, and treatment costs. Consequently, Single Pill combinations are the preferred treatment option in numerous international treatment guidelines, including in the EU and Germany. APONTIS PHARMA has been developing, promoting, and distributing a broad portfolio of Single Pill combinations and other pharmaceutical products since 2013, with a special focus on cardiovascular diseases such as hypertension, hyperlipidemia, and secondary prevention. For additional information about APONTIS PHARMA, please visit www.apontis-pharma.de.

APONTIS PHARMA AG

Investor Relations
ir@apontis-pharma.de
T: +49 2173 89 55 4900
F: +49 2173 89 55 1521
Alfred-Nobel-Str. 10
40789 Monheim am Rhein
Germany
apontis-pharma.de

APONTIS PHARMA Press Contact

CROSS ALLIANCE communication GmbH
Sven Pauly
ir@apontis-pharma.de
T: +49 89 125 09 0330